Literature DB >> 15608078

Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.

Timothy A Esbenshade1, Gerard B Fox, Kathleen M Krueger, Thomas R Miller, Chae Hee Kang, Lynne I Denny, David G Witte, Betty B Yao, Liping Pan, Jill Wetter, Kennan Marsh, Youssef L Bennani, Marlon D Cowart, James P Sullivan, Arthur A Hancock.   

Abstract

Histamine H3 receptor antagonists are being developed to treat a variety of neurological and cognitive disorders that may be ameliorated by enhancement of central neurotransmitter release. Here, we present the in vitro pharmacological and in vivo pharmacokinetic profiles for the nonimidazole, benzofuran ligand ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] and compare it with several previously described imidazole and nonimidazole H3 receptor antagonists. ABT-239 binds to recombinant human and rat H3 receptors with high affinity, with pK(i) values of 9.4 and 8.9, respectively, and is over 1000-fold selective versus human H1, H2, and H4 histamine receptors. ABT-239 is a potent H3 receptor antagonist at recombinant human and rat receptors, reversing agonist-induced changes in cAMP formation (pK(b) = 7.9 and 7.6, respectively), guanosine 5'-O-(3-[35S]thio) triphosphate ([35S]GTPgammaS) binding (pK(b) = 9.0 and 8.3, respectively), and calcium mobilization (human pK(b) = 7.9). ABT-239 also competitively reversed histamine-mediated inhibition of [3H]histamine release from rat brain cortical synaptosomes (pK(b) = 7.7) and agonist-induced inhibition of contractile responses in electric field stimulated guinea pig ileal segments (pA2 = 8.7). Additionally, ABT-239 is a potent inverse agonist, inhibiting constitutive [35S]GTPgammaS binding at both rat and human H3 receptors with respective pEC50 values of 8.9 and 8.2. ABT-239 demonstrates good pharmacokinetic characteristics in rat, dog, and monkey with t1/2 values ranging from 4 to 29 h, corresponding with clearance values and metabolic turnover in liver microsomes from these species, and good oral bioavailability ranging from 52 to 89%. Thus, ABT-239 is a selective, nonimidazole H3 receptor antagonist/inverse agonist with similar high potency in both human and rat and favorable drug-like properties.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15608078     DOI: 10.1124/jpet.104.078303

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Effects of the cognition-enhancing agent ABT-239 on fetal ethanol-induced deficits in dentate gyrus synaptic plasticity.

Authors:  Rafael K Varaschin; Katherine G Akers; Martina J Rosenberg; Derek A Hamilton; Daniel D Savage
Journal:  J Pharmacol Exp Ther       Date:  2010-03-22       Impact factor: 4.030

2.  Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.

Authors:  David G Witte; Betty Bei Yao; Thomas R Miller; Tracy L Carr; Steven Cassar; Rahul Sharma; Ramin Faghih; Bruce W Surber; Timothy A Esbenshade; Arthur A Hancock; Kathleen M Krueger
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

Review 3.  The histamine H3 receptor: an attractive target for the treatment of cognitive disorders.

Authors:  T A Esbenshade; K E Browman; R S Bitner; M Strakhova; M D Cowart; J D Brioni
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

4.  Effects of a novel cognition-enhancing agent on fetal ethanol-induced learning deficits.

Authors:  Daniel D Savage; Martina J Rosenberg; Christina R Wolff; Katherine G Akers; Ahmed El-Emawy; Miranda C Staples; Rafael K Varaschin; Carrie A Wright; Jessica L Seidel; Kevin K Caldwell; Derek A Hamilton
Journal:  Alcohol Clin Exp Res       Date:  2010-07-09       Impact factor: 3.455

5.  Modulation of prepulse inhibition and stereotypies in rodents: no evidence for antipsychotic-like properties of histamine H3-receptor inverse agonists.

Authors:  Aude Burban; Chit Sadakhom; Dominique Dumoulin; Christiane Rose; Gwenaëlle Le Pen; Henriette Frances; Jean-Michel Arrang
Journal:  Psychopharmacology (Berl)       Date:  2010-05-01       Impact factor: 4.530

6.  Structure-based prediction of subtype selectivity of histamine H3 receptor selective antagonists in clinical trials.

Authors:  Soo-Kyung Kim; Peter Fristrup; Ravinder Abrol; William A Goddard
Journal:  J Chem Inf Model       Date:  2011-11-16       Impact factor: 4.956

7.  Assessment of the abuse liability of ABT-288, a novel histamine H₃ receptor antagonist.

Authors:  Thomas J Hudzik; Ana Basso; Janel M Boyce-Rustay; William Bracken; Kaitlin E Browman; Karla Drescher; Timothy A Esbenshade; Lise I Loberg; James J Lynch; Jorge D Brioni
Journal:  Psychopharmacology (Berl)       Date:  2013-02-28       Impact factor: 4.530

8.  Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil.

Authors:  M Uguen; D Perrin; S Belliard; X Ligneau; P M Beardsley; J M Lecomte; J C Schwartz
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

9.  Impact of histaminergic H3 receptor antagonist on hypoglossal nucleus in chronic intermittent hypoxia conditions.

Authors:  Liang Xie; Qinhan Wu; Weiping Hu; Xu Wu; Guiling Xiang; Shengyu Hao; Han Guo; Shanqun Li
Journal:  Psychopharmacology (Berl)       Date:  2020-09-22       Impact factor: 4.530

10.  Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists.

Authors:  T R Miller; I Milicic; J Bauch; J Du; B Surber; K E Browman; K Marsh; M Cowart; J D Brioni; T A Esbenshade
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.